Medigene AG Set to Showcase Cancer Innovations
Medigene AG (FSE: MDG1), an oncology platform company dedicated to pioneering T cell receptor (TCR)-guided therapies for treating cancer, is gearing up for a significant presence at prestigious scientific conferences this November. The company aims to reveal its latest advancements during the 16th Annual Protein & Antibody Engineering Summit (PEGS) and the 2024 Cell conference by Oxford Global. In addition, Medigene will display posters outlining its innovative research at the 39th Society for Immunotherapy of Cancer (SITC).
Highlighting Cutting-Edge Research at PEGS 2024
Medigene will make a notable oral presentation at PEGS 2024, which will take place in Barcelona, focusing on advancements in TCR technologies.
Details of the PEGS Presentation
Scheduled for November 7, a key voice, Dr. Kanuj Mishra, will lead a discussion on the significant potential of Medigene's UniTope and TraCR technologies. This advanced system enhances T cell receptor tagging and tracking, crucial for hybrid therapies leveraging TCRs.
Dr. Mishra will present under the theme of Next-Generation Immunotherapies. His session will delve into the methodology behind a universal epitope merged into recombinant TCRs to facilitate efficient tracking of TCR-T cells expressing the 3S TCR.
Engaging with Experts at Cell 2024
Additionally, Medigene's presence at the Cell 2024 conference highlights the company's commitment to advancing understanding in immunotherapy. Participants can anticipate a panel discussion featuring leading figures in the industry.
Panel Discussion Insights
On November 6, at Novotel London West, attendees will engage with Dr. Kirsty Crame as she leads discussions on autologous versus allogenic therapies, setting the stage for a rich exchange of ideas and innovations in the immunotherapy space.
Keynote Address on Next-Gen Therapies
The following day, Dr. Crame will return to deliver a keynote address titled 'Making The Ordinary Extraordinary: MDG1015 – A Clinic Ready 3rd Generation TCR-T Therapy.' This talk promises to share valuable insights into Medigene's lead TCR-T therapy program, MDG1015, designed to target solid tumors effectively.
Poster Presentations at SITC 2024
Medigene will also participate in the SITC 2024 conference in Houston, where two informative poster presentations will showcase innovative research related to TCR-T therapies.
Exploring Novel Technologies
The first poster, led by Dr. Barbara Loesch and her team, discusses the innovative 'UniTope & TraCR' system, emphasizing its capacity for robust tagging and tracking solutions in TCR-T cells incorporated into recombinant therapies. The work presented aims to revolutionize how researchers and clinicians can monitor TCR interactions.
Furthermore, an IFN-? Biosensor
The second poster presentation sheds light on the 'IFN-? Biosensor,' a universal detection tool for assessing immune responses in varied cellular environments. This technology has remarkable implications for immunotherapy efficacy, enabling researchers to accurately track cellular interactions.
About Medigene AG's Commitment
Medigene AG is on a mission to revolutionize cancer treatment with tailored therapies through its End-to-End Platform. The company is dedicated to developing unique TCRs that are sensitive, specific, and safe, integral to resilience against inhibitors in the tumor microenvironment.
With the recent IND approval for MDG1015, Medigene is poised to file a Clinical Trial Application further enhancing its reputation among global leaders in immuno-oncology. Patients around the world could benefit significantly from these innovative therapies, especially those targeted at solid tumors.
Frequently Asked Questions
What is Medigene AG?
Medigene AG is an oncology company focused on developing TCR-guided therapies to treat cancer effectively.
What conferences will Medigene AG be attending?
Medigene AG will present at the PEGS 2024 and Cell 2024 conferences, as well as showcase research at the SITC 2024 conference.
What is the significance of the MDG1015 therapy?
MDG1015 represents a next-generation TCR-T therapy targeting solid tumors, promising enhanced safety and efficacy in treatment.
Who are the key speakers at these events?
Dr. Kanuj Mishra and Dr. Kirsty Crame are among the prominent speakers representing Medigene AG at these upcoming conferences.
How can I get more information about Medigene AG?
For more information, please contact Medigene AG directly or visit their official website.